This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Chromogranin A (CgA) and chromogranin B (CgB)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Chromogranin A (CgA)

  • a secretory granule which is located alongside specific hormones in large dense-core vesicles of neuronal and neuroendocrine cells

Chromogranin B (CgB)

  • like CgA, widely distributed in neuroendocrine cells, although CgA seems to be more widespread

Plasma CgA may be elevated in neuroendocrine tumours

  • one study revealed that plasma CgA was elevated in 94% of endocrine pancreatic tumours
  • there is study evidence that elevated CgA levels are even more frequent (99%) in malignant carcinoid and gastroenteropancreatic tumours (99%) - the highest levels seen in metastatic carcinoid particularly midgut)

Plasma CgB (and its 74-amino-acid fragment termed GAWK) is generally a better marker for benign insulin-producing tumours than CgA.

Staining for the chromogranins in different neuroendocrine tumours has revealed that CgA seems more ubiquitous than CgB with the exception of the CgB-staining pituitary lactotrophs and some pancreatic beta-cell tumours.

Reference:

  1. Endocr Relat Cancer. 2004 Mar;11(1):1-18.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.